SAN DIEGO, June 7, 2021 /PRNewswire/ -- Kintara
Therapeutics, Inc. (Nasdaq: KTRA) ("Kintara" or the "Company"), a
biopharmaceutical company focused on the development of new solid
tumor cancer therapies, today announced Kintara's addition to the
Russell MicrocapÒ Index. This milestone will take
place at the conclusion of the 2021 Russell Indexes' annual
reconstitution, effective after the U.S. market opens on
June 28, 2021 according to a
preliminary list of additions posted June 4,
2021.
"We are delighted for Kintara to have been added to the FTSE
Russell Microcap® Index, which will help increase investor
exposure to our Company's mission of developing novel cancer
therapies for patients with unmet medical needs," said Saiid Zarrabian, CEO of Kintara. "We look
forward to the opportunity to expand awareness of our late-stage
oncology pipeline of which our lead product, VAL-083, is currently
being tested in GCAR's GBM AGILE registrational study for all three
GBM patient subtypes of newly-diagnosed methylated MGMT,
newly-diagnosed unmethylated MGMT, and recurrent GBM."
Membership in the Russell Microcap® Index, which remains in
place for one year, means automatic inclusion in the appropriate
growth and value style indexes. FTSE Russell determines membership
for its Russell Indexes primarily by objective,
market-capitalization rankings, and style attributes.
Russell Indexes are widely used by investment managers and
institutional investors for index funds and as benchmarks for
active investment strategies. Approximately $10.6 trillion in assets are benchmarked against
Russell's U.S. Indexes. Russell Indexes are part of FTSE Russell, a
leading global index provider.
ABOUT KINTARA
Located in San Diego,
California, Kintara is dedicated to the development of novel
cancer therapies for patients with unmet medical needs.
Kintara is developing two late-stage, Phase 3-ready therapeutics
for clear unmet medical needs with reduced risk development
programs. The two programs are VAL-083 for GBM and REM-001
for cutaneous metastatic breast cancer (CMBC).
VAL-083 is a "first-in-class", small-molecule
chemotherapeutic with a novel mechanism of action that has
demonstrated clinical activity against a range of cancers,
including central nervous system, ovarian and other solid tumors
(e.g., NSCLC, bladder cancer, head and neck) in U.S. clinical
trials sponsored by the National Cancer Institute (NCI). Based on
Kintara's internal research programs and these
prior NCI-sponsored clinical studies, Kintara is
currently conducting clinical trials to support the development and
commercialization of VAL-083 in GBM.
Kintara is also advancing its proprietary, late-stage
photodynamic therapy platform that holds promise as a localized
cutaneous, or visceral, tumor treatment as well as in other
potential indications. REM-001 therapy, has been previously
studied in four Phase 2/3 clinical trials in patients with CMBC,
who had previously received chemotherapy and/or failed radiation
therapy. With clinical efficacy to date of 80% complete responses
of CMBC evaluable lesions, and with an existing robust safety
database of approximately 1,100 patients across multiple
indications, Kintara is advancing the REM-001 CMBC
program to late-stage pivotal testing.
SAFE HARBOR STATEMENT
Any statements contained in this press release that do not
describe historical facts may constitute forward-looking statements
as that term is defined in the Private Securities Litigation Reform
Act of 1995, including statements regarding the status of the
Company's clinical trials and the GBM AGILE study. Any
forward-looking statements contained herein are based on current
expectations but are subject to a number of risks and
uncertainties. The factors that could cause actual future
results to differ materially from current expectations include, but
are not limited to, risks and uncertainties relating to the impact
of the COVID-19 pandemic on the Company's operations and clinical
trials; the Company's ability to develop, market and sell products
based on its technology; the expected benefits and efficacy of the
Company's products and technology; the availability of substantial
additional funding for the Company to continue its operations and
to conduct research and development, clinical studies and future
product commercialization; and, the Company's business, research,
product development, regulatory approval, marketing and
distribution plans and strategies. These and other factors
are identified and described in more detail in the Company's
filings with the SEC, including the Company's Annual Report on Form
10-K for the year ended June 30,
2020, the Company's Quarterly Reports on Form 10-Q, and the
Company's Current Reports on Form 8-K.
CONTACTS:
Investors:
CORE IR
516-222-2560
ir@coreir.com
Media:
Jules Abraham
Director of Public Relations
CORE IR
917-885-7378
julesa@coreir.com
View original content to download
multimedia:http://www.prnewswire.com/news-releases/kintara-therapeutics-set-to-join-russell-microcap-index-301306592.html
SOURCE Kintara Therapeutics